Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by capebretongirlon Jul 29, 2021 2:36pm
122 Views
Post# 33626590

WAY FORWARD

WAY FORWARDWe have seen very low volumes of late which is a negative for any stock. The positive is that the confirmation of the CARE deal will happen shortly and the hope is that confirmation will act as a catalyst, along with the August 16 financials.  Revenues from CARE will be incorporated into the quarterly reports from now on and this is a positive development. Q2 with covid revs should also be good and this should help the stock in the short term.

The bashing group here is interesting only from the perspective that they are here on an organized mission - this hapless lot are clearly driven/instructed to attempt to cause dissent and lower the sp at any cost - whether this is for their own shorting gains or working on behalf of someone else is unknown. Fortunately for the stock, they are largely ineffective due to their lack of knowledge and general incompetence - lucky for us.
<< Previous
Bullboard Posts
Next >>